{"result": "(\"entity\"<|>ENFERMEDAD CARDIOVASCULAR<|>EVENT<|>Cardiovascular disease refers to a range of conditions affecting the heart and blood vessels, which are addressed in the guidelines by the European Society of Cardiology.)\n##\n(\"entity\"<|>DIABETES MELLITUS<|>EVENT<|>Diabetes mellitus is a chronic condition that affects how the body processes blood sugar (glucose) and is mentioned in the context of cardiovascular risk assessment.)\n##\n(\"entity\"<|>RIESGO CARDIOVASCULAR<|>EVENT<|>Cardiovascular risk refers to the likelihood of experiencing cardiovascular events, which is classified into different risk groups in the guidelines.)\n##\n(\"entity\"<|>FILTRADO GLOMERULAR<|>EVENT<|>Glomerular filtration rate (GFR) is a test used to check how well the kidneys are working, which is relevant in assessing cardiovascular risk.)\n##\n(\"entity\"<|>SCORE<|>EVENT<|>SCORE is a cardiovascular risk assessment tool used to estimate the risk of cardiovascular events in patients.)\n##\n(\"relationship\"<|>SOCIEDAD EUROPEA DE CARDIOLOGÍA<|>ENFERMEDAD CARDIOVASCULAR<|>The European Society of Cardiology provides guidelines for the prevention and treatment of cardiovascular disease.<|>7)\n##\n(\"relationship\"<|>DIABETES MELLITUS<|>RIESGO CARDIOVASCULAR<|>Diabetes mellitus is a condition that increases the risk of cardiovascular events, as noted in the risk assessment guidelines.<|>6)\n##\n(\"relationship\"<|>FILTRADO GLOMERULAR<|>RIESGO CARDIOVASCULAR<|>Glomerular filtration rate is a factor considered in assessing cardiovascular risk in patients.<|>5)\n##\n(\"relationship\"<|>SCORE<|>RIESGO CARDIOVASCULAR<|>SCORE is used to evaluate and categorize cardiovascular risk in patients based on various health factors.<|>6)\n<|COMPLETE|>", "input": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": [{"role": "user", "content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: astatina                        1-4 mg                       1-4 mg                         1-2 mg                              de al menos un 50% si el colesterol LDL basal oscila entre 70 y 135 mg/dl.\n           Ezetimiba                            10 mg                        10 mg                          10 mg\n           Fenofibrato                           96 mg                       48 mg                           Evitar                             Riesgo alto\n           Gemfibrozilo                        1.200 mg                     600 mg              600 mg (evitar si FGe < 15)                     Este grupo incluye: 1) sujetos con un factor de riesgo marcadamente elevado, como las dis-\n           ω-3                                   2-4 g                        2-4 g                          2-4 g                              lipidemias familiares (en general, considerando un colesterol total > 310 mg/dl) o la hiper-\n         * Experiencia limitada con dosis superiores en FG < 30 ml/min.                                                                         tensión arterial grave (considerando cifras de presión arterial sistólica y diastólica > 180/\n         ** Contraindicada según ficha técnica de la AEMPS.                                                                                     110 mmHg); 2) diabetes mellitus sin otro factor de riesgo cardiovascular o lesión de órgano\n         Referencias:                                                                                                                           diana    (excepto    los  pacientes jóvenes        con   diabetes     tipo 1   sin  factores de riesgo,       que   se\n         • Amor Fernández AJ, Vinagre Torres I, Perea Castilla V. Manual de Endocrinología y Nutrición [Internet]. Madrid: Sociedad Española    podrían clasificar de riesgo bajo o moderado); 3) insuficiencia renal crónica moderada (fil-\n           de Endocrinología y Nutrición; 2018. Capítulo 125. Tratamiento de las dislipemias. [citado 11 de noviembre de 2019]. Disponible en:  trado glomerular estimado entre 30 y 59 ml/min/1,73 m2), y 4) un riesgo estimado mediante\n           https://manual.seen.es/article?id=5559fe85-9644-42fd-966a-6a43ac18103c\n                                                                                                                                                SCORE ≥ 5%, pero <10%.\n         La Sociedad Europea de Cardiología (2016) considera como grupo de muy alto                                                             El objetivo terapéutico, en este grupo, es un colesterol LDL < 100 mg/dl o una reducción de\n     29                                                                                                                                         al menos un 50% si el colesterol LDL está comprendido entre 100 y 200 mg/dl.\n         riesgo todas las siguientes situaciones excepto una. Señálela:\n         A. Enfermedad cardiovascular documentada.                                                                                              Riesgo moderado\n         B. Paciente con diabetes mellitus con microalbuminuria.                                                                                Este grupo incluye a aquellos sujetos con un riesgo SCORE ≥ 1%, pero <5%, y sin ninguna de\n         C.  Paciente con riesgo estimado de muerte de causa cardiovascular (SCORE) entre el 5% y el 10%.                                       las condiciones de los supuestos de riesgo alto o muy alto.\n         D.  Paciente con filtrado glomerular estimado de 25 ml/min/1,73 m2.                                                                    El objetivo terapéutico, en este grupo, es un colesterol LDL < 115 mg/dl.\n                                                                                                                                                Riesgo bajo\n         COMENTARIO                                                                                                                             Este grupo incluye a aquellos sujetos con un riesgo SCORE < 1% y sin ninguna de las condi-\n         Desde la Sociedad Europea de Cardiología y otras sociedades europeas de prevención de la                                               ciones de los supuestos de riesgo alto o muy alto.\n         enfermedad cardiovascular, se actualizaron en 2016 las Guías Europeas de Prevención de                                                 El objetivo terapéutico, en este grupo, es similar al de riesgo moderado: colesterol LDL <\n         la Enfermedad Cardiovascular en la Práctica Clínica, en las que se clasifica a los pacientes                                           115 mg/dl.\n         en cuatro grupos de riesgo cardiovascular y se marcan unas recomendaciones de trata-\n         miento según el riesgo estimado:                                                                                                       Referencias:\n                                                                                                                                                • Amor Fernández AJ, Vinagre Torres I, Perea Castilla V. Manual de Endocrinología y Nutrición [Internet]. Madrid: Sociedad Española\n                                                                                                                                                  de Endocrinología y Nutrición; 2018. Capítulo 125. Tratamiento de las dislipemias. [citado 11 de noviembre de 2019]. Disponible en:\n         Riesgo muy alto                                                                                                                          https://manual.seen.es/article?id=5559fe85-9644-42fd-966a-6a43ac18103c\n         Este   grupo     incluye:   1)  enfermedad       cardiovascular       documentada         clínica   o  por   imagen.\n         La clínica incluye infarto de miocardio previo, síndrome coronario agudo, revasculariza-\n\n\n\n456                                                                                                                                                                                                                                                                       457\n---\n                                                                                                                                                                                                        OBESIDAD,              LÍPIDOS                     8\n                                                                                                                                                                            Y TRASTORNOS ELECTROLÍTICOS\n\n\n\n     30  Hombre de 34 años, remitido a la consulta\n######################\nOutput:"}, {"role": "assistant", "content": "(\"entity\"<|>SOCIEDAD EUROPEA DE CARDIOLOGÍA<|>ORGANIZATION<|>The European Society of Cardiology is an organization that updates guidelines for cardiovascular disease prevention and treatment in clinical practice.)\n##\n(\"entity\"<|>AMOR FERNÁNDEZ<|>PERSON<|>Amor Fernández is an author of the Manual de Endocrinología y Nutrición, which discusses treatment for dyslipidemias.)\n##\n(\"entity\"<|>MADRID<|>GEO<|>Madrid is the capital of Spain and the location of the Sociedad Española de Endocrinología y Nutrición.)\n##\n(\"entity\"<|>MANUAL DE ENDOCRINOLOGÍA Y NUTRICIÓN<|>EVENT<|>The Manual de Endocrinología y Nutrición is a publication that provides guidelines and recommendations for the treatment of dyslipidemias.)\n##\n(\"entity\"<|>DISLIPIDEMIAS<|>EVENT<|>Dyslipidemias refer to abnormal levels of lipids in the blood, which are addressed in the guidelines by the European Society of Cardiology.)\n##\n(\"relationship\"<|>AMOR FERNÁNDEZ<|>MANUAL DE ENDOCRINOLOGÍA Y NUTRICIÓN<|>Amor Fernández is one of the authors of the Manual de Endocrinología y Nutrición, which discusses treatment for dyslipidemias.<|>8)\n##\n(\"relationship\"<|>SOCIEDAD EUROPEA DE CARDIOLOGÍA<|>MANUAL DE ENDOCRINOLOGÍA Y NUTRICIÓN<|>The European Society of Cardiology references the Manual de Endocrinología y Nutrición in its guidelines for cardiovascular disease prevention.<|>7)\n##\n(\"relationship\"<|>SOCIEDAD EUROPEA DE CARDIOLOGÍA<|>DISLIPIDEMIAS<|>The European Society of Cardiology provides guidelines for the treatment of dyslipidemias as part of its cardiovascular disease prevention efforts.<|>6)\n##\n(\"relationship\"<|>MADRID<|>SOCIEDAD EUROPEA DE CARDIOLOGÍA<|>The European Society of Cardiology is based in Madrid, Spain.<|>5)\n<|COMPLETE|>"}]}